Hyperuricemia is associated with an increased prevalence of ventricular tachycardia and fibrillation in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention

Table 3 nsVT, SVT/VF and in-hospital clinical outcomes of the patients with STEMI stratified by the presence of hyperuricemia

	Patients with hyperuricemia	Patients without hyperuricemia	p value
	(n = 147)	(n = 487)
	Serum uric acid 8.9 (7.1–8.9) mg/dl	Serum uric acid 5.0 (4.1–5.7) mg/dl
Ventricular tachycardia	28 (19.0%)	46 (9.4%)	0.001
nsVT by Holter monitoring	23 (15.6%)	42 (8.6%)	0.003
SVT/VF by cardiac monitoring	6^a (4.1%)	4 (0.8%)	0.013
Clinical outcomes
Death	10 (6.8%)	5 (1.0%)	0.000
Acute heart failure	25 (17.0%)	29 (6.0%)	0.000
Stent thrombosis	0 (0%)	0 (0%)
Target lesion revascularization	0 (0%)	0 (0%)

Sample size, n = 634. Data are expressed as number of patients (percentage)
nsVT, non-sustained ventricular tachycardia; SVT, sustained ventricular tachycardia; VF, ventricular fibrillation; STEMI, ST-segment elevation myocardial infarction
^aOne patient developed both nsVT on Holter and SVT on cardiac monitoring

ISSN: 1471-2261